
Avalo Therapeutics (AVTX) Stock Forecast & Price Target
Avalo Therapeutics (AVTX) Analyst Ratings
Bulls say
Avalo Therapeutics is supported by compelling clinical validation for abdakibart, with the Phase 2 LOTUS study in hidradenitis suppurativa (n=253) meeting its primary endpoint and delivering a 42.5% combined HiSCR75 response rate, the highest absolute improvement seen in trials of similar size or larger. Its differentiated profile—selective high-affinity IL-1β blockade, favorable safety, early effects on draining tunnels, and dosing potential out to Q4W—positions it as a credible later-line option even after AbbVie’s weaker-than-expected lutikizumab data. Fundamentally, the company’s positive outlook is reinforced by a well-funded balance sheet with $462.8M in cash, expected to fund operations into 2029, while Phase 3 initiation is targeted for 1H27 and could unlock significant upside in a large, underpenetrated HS market.
Bears say
Avalo Therapeutics is viewed negatively because the newly disclosed INTREPID data materially weaken confidence that IL-1 inhibition will translate into a durable competitive advantage in hidradenitis suppurativa, with an 8-point placebo-adjusted HiSCR75 benefit versus 31.4% active response and a 13-point contraction from Phase 2 driven largely by lower active-arm efficacy. That read-through directly pressures abdakibart, whose 17.2-point LOTUS result now faces the risk of similar Phase 2-to-Phase 3 erosion, while Avalo’s valuation is increasingly anchored to cash rather than pipeline value given a market cap of about $425M against $472.2M of cash and investments at June 30. The company also used $37.7M in operating cash during 1H26, guides runway into 2029, and still must fund Phase 3 initiation in 1H27 and a $10M milestone, leaving both abdakibart and AVTX-010 exposed to the same pathway risk.
This aggregate rating is based on analysts' research of Avalo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Avalo Therapeutics (AVTX) Analyst Forecast & Price Prediction
Start investing in Avalo Therapeutics (AVTX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Avalo Therapeutics (AVTX) Forecast
Avalo Therapeutics (AVTX) Analyst Forecast & Price Prediction
Start investing in Avalo Therapeutics (AVTX)
Order type
Buy in
Order amount
Est. shares
0 shares